Company Overview

Rafael Holdings, Inc. is a diversified holding company operating across life sciences, pharmaceuticals, real estate, and technology-enabled health research. The company’s core strategy is to own and allocate capital to a portfolio of operating businesses and assets, rather than conduct material operating activities directly. Rafael Holdings is publicly traded on the NYSE under the ticker RFL and is controlled by the Jonas family through super-voting shares.

The company’s primary value drivers are its majority ownership interest in Rafael Pharmaceuticals, Inc., ownership of clinical-stage and research-focused life science subsidiaries, and a commercial real estate portfolio primarily located in New Jersey. Rafael Holdings was formed in 2017 following a corporate reorganization and IPO, evolving from assets previously held within IDT Corporation. Its strategic positioning centers on long-duration investments in drug development and biomedical innovation, supported by stable real estate income and a strong balance sheet.

Business Operations

Rafael Holdings generates value through ownership and oversight of distinct business lines rather than consolidated operating revenue. Its principal segments include life sciences and pharmaceuticals, real estate operations, and other investments and intellectual property-related activities. The company does not currently rely on product sales as a primary revenue source; instead, it depends on rental income, intercompany arrangements, and the long-term appreciation of its operating subsidiaries.

In life sciences, the company’s most significant asset is Rafael Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing oncology and metabolic disease therapies, including devimistat. Additional subsidiaries include Cornerstone Pharmaceuticals, Barer Institute, and Day Three Labs, which support drug development, biomedical research, and early-stage health innovation. Real estate operations consist primarily of commercial office and laboratory properties leased to third parties and affiliates, predominantly within the United States.

Strategic Position & Investments

Rafael Holdings’ strategy emphasizes long-term capital deployment into high-risk, high-reward biomedical innovation, particularly in oncology and rare or metabolic diseases. The company continues to fund clinical development at Rafael Pharmaceuticals, Inc., which represents its most material investment and primary source of potential future value creation. Investment decisions are centralized and closely aligned with controlling shareholders and senior leadership.

The company has historically favored internal incubation and majority ownership rather than broad acquisition-driven expansion. Its portfolio reflects a deliberate concentration in life sciences, supported by infrastructure investments such as laboratory facilities and research institutes. While emerging technologies in oncology metabolism and translational medicine are central to its strategy, the ultimate commercial outcomes of these investments remain uncertain based on publicly available data.

Geographic Footprint

Rafael Holdings’ operations are primarily concentrated in the United States, with headquarters in Newark, New Jersey. Its real estate assets and corporate offices are largely located in New Jersey, providing regional stability and proximity to major pharmaceutical and academic research hubs.

Through Rafael Pharmaceuticals, Inc., the company has an indirect international footprint tied to global clinical trials, regulatory interactions, and research collaborations, including activities in North America and Europe. However, Rafael Holdings does not maintain significant standalone international operating subsidiaries, and its global exposure is largely investment-driven rather than operational.

Leadership & Governance

Rafael Holdings is led by its founder and controlling shareholder, with governance structured to support long-term strategic control. The leadership team emphasizes capital discipline, scientific rigor, and patient-focused drug development, particularly within its life sciences portfolio. The board and executive leadership maintain close oversight of subsidiary operations and investment allocation.

Key executives include:

• Howard Jonas – Chairman of the Board and Chief Executive Officer
• Daniel Jonas – President
• David Goldstein – Chief Financial Officer
• Steven R. Himes – Chief Accounting Officer
• Jack Brown – Executive Vice President, General Counsel and Secretary

The company’s governance structure includes dual-class voting shares, providing insiders with enhanced voting control, a model intended to support long-term investment horizons rather than short-term market pressures.